Journal of Literature Pharmacy Sciences

Potential Use and Effects of Essential Oils in SARS-CoV-2 (COVID-19): Traditional Review
Uçucu Yağların SARS-CoV-2'de (COVID-19) Potansiyel Kullanımı ve Etkileri: Geleneksel Derleme
Eda AVCIa,b, Alev ÖNDERb
aAnkara Medipol University Faculty of Pharmacy, Department of Pharmacognosy, Ankara, Türkiye
bAnkara University Faculty of Pharmacy, Department of Pharmacognosy, Ankara, Türkiye
J Lit Pharm Sci. 2024;13(1):18-27
doi: 10.5336/pharmsci.2023-97301
Article Language: EN
Full Text
ABSTRACT
 Severe acute respiratory syndrome-coronavirus-2 (SARS-COV-2), a new type of beta coronavirus that emerged in Wuhan, China, and caused a pandemic, was declared coronavirus disease-2019 (COVID-19) by the World Health Organization on February 12, 2020. Natural remedies from plants have been used traditionally for thousands of years. The global interest in drug development from natural products has grown tremendously. The interest in essential oils, which attract attention with their rich and original content, is increasing in this direction. It is thought that essential oils, which are effective against various microorganisms, may help treat COVID-19 due to their anti-inflammatory, immunomodulatory, bronchodilator, antibacterial, and antiviral properties. This review briefly describes the current biology, epidemiology, and clinical aspects of COVID-19 and essential oil's activity on SARS-COV-2 by considering its effectiveness in this field. It has been observed that most of the studies on this subject consist of in silico and in vitro studies. In this context, molecular docking studies have come into prominence. However, in vivo and clinical studies of essential oils with notable antiviral-antibacterial effects must be increased. Therefore, essential oils and their active components will be promising potential drug candidates against COVID-19, and their numbers will potentially grow. In conclusion, the present review is focused on the most common and well-known essential oils available on the pharmaceutical markets, which show visible activities, especially against enveloped viruses, including COVID-19.

Keywords: Antiviral agents; COVID-19; essential oils; eucalyptol
ÖZET
 Çin'in Wuhan eyaletinde ortaya çıkarak pandemiye sebep olan yeni bir beta-koronavirüs türü olan şiddetli akut solunum sendromukoronavirüs-2 [severe acute respiratory syndrome-coronavirus-2 (SARS-COV-2)], Dünya Sağlık Örgütü tarafından, 12 Şubat 2020 tarihinde koronavirüs hastalığı-2019 [coronavirus disease-2019 (COVID19)] olarak ilan edildi. Bitkilerden elde edilen doğal ilaçlar, geleneksel olarak yıllardır kullanılmaktadır. Doğal ürünlerden ilaç geliştirmeye yönelik küresel ilgi, son yıllarda büyük oranda artış göstermektedir. Zengin ve özgün içerikleri ile dikkat çeken uçucu yağlara olan ilgi de bu doğrultuda giderek artmaktadır. Çeşitli mikroorganizmalara karşı etkili olan uçucu yağların antiinflamatuar, immünomodülatör, bronkodilatör, antibakteriyel ve antiviral özellikleri nedeniyle COVID-19 tedavisinde faydalı olabilecekleri düşünülmektedir. Bu derlemede, COVID-19'un mevcut biyolojisi, epidemiyolojisi ile çeşitli klinik yönleri kısaca anlatılmış ve bu alan etkili görülerek ön plana çıkmış uçucu yağlardan bahsedilmiştir. Bu konudaki çalışmaların büyük kısmının in silico ve in vitro çalışmalarından oluştuğu görülmüştür. Bu bağlamda moleküler docking çalışmaları ön plana çıkmaktadır. Ancak güçlü antiviral-antibakteriyel etkili uçucu yağlar başta gelmek üzere, in vivo ve klinik çalışmaların da artırılması gerektiği düşünülmektedir. Bu sayede uçucu yağlar ve etkili bileşenlerinin COVID-19'a karşı potansiyel ilaç adayları olabilecekleri umut edilmektedir. Mevcut incelemenin verileri, farmasötik pazarda mevcut olan ve özellikle zarflı virüslere karşı gözle görülür aktiviteler gösteren en yaygın ve çok bilinen uçucu yağlara dair bilgi vermek için odaklanmıştır.

Anahtar Kelimeler: Antiviral ajanlar; COVID-19; uçucu yağlar; ökaliptol
REFERENCES:
  1. Geller C, Varbanov M, Duval RE. Human coronaviruses: insights into environmental resistance and its influence on the development of new antiseptic strategies. Viruses. 2012;4(11):3044-68. [Crossref]  [PubMed]  [PMC] 
  2. Phan T. Novel coronavirus: From discovery to clinical diagnostics. Infect Genet Evol. 2020;79:104211. [Crossref]  [PubMed]  [PMC] 
  3. Dhama K, Khan S, Tiwari R, Sircar S, Bhat S, Malik YS, et al. Coronavirus disease 2019-COVID-19. Clin Microbiol Rev. 2020;33(4):e00028-20. [Crossref]  [PubMed]  [PMC] 
  4. Moein ST, Hashemian SM, Mansourafshar B, Khorram-Tousi A, Tabarsi P, Doty RL. Smell dysfunction: a biomarker for COVID-19. Int Forum Allergy Rhinol. 2020;10(8):944-50. [Crossref]  [PubMed]  [PMC] 
  5. Yuen KS, Ye ZW, Fung SY, Chan CP, Jin DY. SARS-CoV-2 and COVID-19: The most important research questions. Cell Biosci. 2020;10:40. [Crossref]  [PubMed]  [PMC] 
  6. Chan JF, Lau SK, To KK, Cheng VC, Woo PC, Yuen KY. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev. 2015;28(2):465-522. [Crossref]  [PubMed]  [PMC] 
  7. Akilligöz Y, Basaran A. Ankara ilinde yapılan etnobotanik çalışmaların, Covid-19 pandemisi üzerinde değerlendirilmesi [Evaluation of ethnobotanical studies conducted in Ankara province on Covid-19 pandemic]. Journal of Integrative and Anatolian Medicine. 2021;2(3):20-55. [Crossref] 
  8. Kadam SB, Sukhramani GS, Bishnoi P, Pable AA, Barvkar VT. SARS-CoV-2, the pandemic coronavirus: Molecular and structural insights. J Basic Microbiol. 2021;61(3):180-202. [Crossref]  [PubMed]  [PMC] 
  9. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020;92(4):418-23. Erratum in: J Med Virol. 2020;92(10):2249. [Crossref]  [PubMed]  [PMC] 
  10. Baris E, Gumustekin M, Arici MA. COVID-19 tedavisinde kullanılan ilaçların güvenliliği [Safety of drugs used in the treatment of Covid-19]. J DEU Med. 2021;35(50):19-33. [Crossref] 
  11. Koyama S, Kondo K, Ueha R, Kashiwadani H, Heinbockel T. Possible use of phytochemicals for recovery from COVID-19-induced anosmia and ageusia. Int J Mol Sci. 2021;22(16):8912. [Crossref]  [PubMed]  [PMC] 
  12. Liu JZ, Lyu HC, Fu YJ, Cui Q. Amomum tsao-ko essential oil, a novel anti-COVID-19 Omicron spike protein natural products: A computational study. Arab J Chem. 2022;15(7):103916. [Crossref]  [PubMed]  [PMC] 
  13. Lam S, Lombardi A, Ouanounou A. COVID-19: A review of the proposed pharmacological treatments. Eur J Pharmacol. 2020;886:173451. [Crossref]  [PubMed]  [PMC] 
  14. Khaliq B, Ali N, Akrem A, Ashraf MY, Malik A, Tahir A, Zia-Ul-Haq M. Medicinal plants against Covid-19. In: Ahmedah HT, Riaz M, Sagheer A, Moga MA, eds. The Covid-19 Pandemic: A Multidisciplinary Review of Diagnosis, Prevention, and Treatment. 1st ed. Taylor & Francis eBooks DRM Free Collection; 2022. p.297-337. [Crossref] 
  15. Chilamakuri R, Agarwal S. COVID-19: Characteristics and Therapeutics. Cells. 2021;10(2):206. [Crossref]  [PubMed]  [PMC] 
  16. Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol. 2016;3(1):237-61. [Crossref]  [PubMed]  [PMC] 
  17. Serrano-Barrera OR. Phylogenetic analysis of the human receptor of SARS-CoV-2 coronavirus and its implications for the biology of infection. Revista Electrónica Dr Zoilo E Marinello Vidaurreta. 2020;45(3). [Link] 
  18. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol. 2020;94(7):e00127-20. [Crossref]  [PubMed]  [PMC] 
  19. Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ. 2020;371:m3862. [Crossref]  [PubMed] 
  20. Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, et al. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020;126(10):1456-74. [Crossref]  [PubMed]  [PMC] 
  21. Adao R, Guzik JT. Inside the heart of Covid-19. Cardiovascular Research. American Medical Association. 2020;323(11):1061-9. [Crossref]  [PubMed]  [PMC] 
  22. Gąsecka A, Borovac JA, Guerreiro RA, Giustozzi M, Parker W, Caldeira D, et al. Thrombotic complications in patients with COVID-19: pathophysiological mechanisms, diagnosis, and treatment. Cardiovasc Drugs Ther. 2021;35(2):215-29. [Crossref]  [PubMed]  [PMC] 
  23. Alp Ş, Ünal S. Yeni koronavirüs (SARS-CoV-2) kaynaklı pandemi: Gelişmeler ve güncel durum [Novel coronavirus (SARS-CoV-2) pandemic: overview and current status]. Flora the Journal of Infectious Diseases and Clinical Microbiology. 2020;25(2):111-20. [Crossref] 
  24. Guo S, Geng Z, Zhang W, Liang J, Wang C, Deng Z, et al. The chemical composition of essential oils from cinnamomum camphora and their insecticidal activity against the stored product pests. Int J Mol Sci. 2016;17(11):1836. [Crossref]  [PubMed]  [PMC] 
  25. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934-43. Erratum in: JAMA Intern Med. 2020;180(7):1031. [Crossref]  [PubMed]  [PMC] 
  26. Tirado-Kulieva VA, Hernández-Martínez E, Choque-Rivera TJ. Phenolic compounds versus SARS-CoV-2: An update on the main findings against COVID-19. Heliyon. 2022;8(9):e10702. [Crossref]  [PubMed]  [PMC] 
  27. Swamy MK, Akhtar MS, Sinniah UR. Antimicrobial properties of plant essential oils against human pathogens and their mode of action: an updated review. Evid Based Complement Alternat Med. 2016;2016:3012462. [Crossref]  [PubMed]  [PMC] 
  28. Amira L, Mansour A, Bechlem H. Systematic review essential oils for SARS-CoV-2 prevention and treatment: Systematic review. J Mol Pharm Sci. 2021;1(1):53-63. [Link] 
  29. Malabadi RB, Kolkar KP, Meti NT, Chalannavar RK. Role of botanical essential oils as a therapy for controlling coronavirus (SARS-CoV-2) disease (Covid-19). International Journal of Research and Scientific Innovation. 2021;8(4):105-18. [Crossref] 
  30. Palai S, Kesh SS. Essential oils: An effective therapeutic strategy against SARS-CoV-2. International Journal of Bio-resource and Stress Management. 2021;12(6):719-24. [Crossref] 
  31. Silva JKRD, Figueiredo PLB, Byler KG, Setzer WN. Essential Oils as Antiviral Agents. Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation. Int J Mol Sci. 2020;21(10):3426. [Crossref]  [PubMed]  [PMC] 
  32. Rathod R, Mohindra R, Vijayakumar A, Soni RK, Kaur R, Kumar A, et al. Essential oil nebulization in mild COVID-19(EONCO): Early phase exploratory clinical trial. J Ayurveda Integr Med. 2022;13(3):100626. [Crossref]  [PubMed]  [PMC] 
  33. Asif M, Saleem M, Saadullah M, Yaseen HS, Al Zarzour R. COVID-19 and therapy with essential oils having antiviral, anti-inflammatory, and immunomodulatory properties. Inflammopharmacology. 2020;28(5):1153-61. Erratum in: Inflammopharmacology. 2021;29(2):577. [Crossref]  [PubMed]  [PMC] 
  34. Kulkarni SA, Nagarajan SK, Ramesh V, Palaniyandi V, Selvam SP, Madhavan T. Computational evaluation of major components from plant essential oils as potent inhibitors of SARS-CoV-2 spike protein. J Mol Struct. 2020;1221:128823. [Crossref]  [PubMed]  [PMC] 
  35. Yadalam PK, Varatharajan K, Rajapandian K, Chopra P, Arumuganainar D, Nagarathnam T, et al. Antiviral essential oil components against SARS-CoV-2 in pre-procedural mouth rinses for dental settings during COVID-19: A Computational Study. Front Chem. 2021;9:642026. [Crossref]  [PubMed]  [PMC] 
  36. Li J, Chen W, Liu H, Liu H, Xiang S, You F, et al. Pharmacologic effects approach of essential oils and their components on respiratory diseases. J Ethnopharmacol. 2023;304:115962. [Crossref]  [PubMed] 
  37. Valussi M, Antonelli M, Donelli D, Firenzuoli F. Appropriate use of essential oils and their components in the management of upper respiratory tract symptoms in patients with COVID-19. J Herb Med. 2021;28:100451. [Crossref]  [PubMed]  [PMC] 
  38. Hawkins J, Hires C, Keenan L, Dunne E. Aromatherapy blend of thyme, orange, clove bud, and frankincense boosts energy levels in post-COVID-19 female patients: A randomized, double-blinded, placebo controlled clinical trial. Complement Ther Med. 2022;67:102823. [Crossref]  [PubMed]  [PMC] 
  39. Sharma AD, Kaur I. Jensenone from eucalyptus essential oil as a potential inhibitor of Covid 19 corona virus infection. Research & Reviews in Biotechnology & Biosciences. 2020;7(1):59-66. [Link] 
  40. Sharma AD, Kaur I. Molecular docking and pharmacokinetic screening of eucalyptol (1,8 cineole) from eucalyptus essential oil against SARS-CoV-2. Not Sci Biol. 2020;12(3):536-45. [Crossref] 
  41. Sharma AD, Kaur I. Eucalyptus essential oil bioactive molecules from against SARS-CoV-2 spike protein: insights from computational studies. Res Sq. 2021. [Crossref] 
  42. Panikar S, Shoba G, Arun M, Sahayarayan JJ, Usha Raja Nanthini A, Chinnathambi A, et al. Essential oils as an effective alternative for the treatment of COVID-19: Molecular interaction analysis of protease (Mpro) with pharmacokinetics and toxicological properties. J Infect Public Health. 2021;14(5):601-10. [Crossref]  [PubMed]  [PMC] 
  43. Ojah EO. Exploring essential oils as prospective therapy against the ravaging coronavirus (SARS-CoV-2). Iberoamerican Journal of Medicine. 2020;4(2):322-30. [Crossref] 
  44. Tshibangu DST, Matondo A, Lengbiye EM, Inkoto CL, Ngoyi EM, Kabengele CN, et al. Possible effect of aromatic plants and essential oils against Covid-19: review of their antiviral activity. Journal of Complementary and Alternative Medical Research. 2020;11(1):10-22. [Crossref] 
  45. Fazmiya MJA, Sultana A, Rahman K, Heyat MBB, Sumbul, Akhtar F, et al. Current Insights on Bioactive Molecules, Antioxidant, Anti-Inflammatory, and Other Pharmacological Activities of Cinnamomum camphora Linn. Oxid Med Cell Longev. 2022;2022:9354555. [Crossref]  [PubMed]  [PMC] 
  46. Ahmed NZ, John Davis GD, Khan AA, Prabhakar L, Ram Paratap M, Afnaan Z, Devi Sri M, Anwar N. Arq Ajīb-a wonder Unani formulation for inhibiting SARS-CoV-2 spike glycoprotein and main protease-an in silico approach. J Complement Integr Med. 2022;9(6):152-5. [Crossref]  [PubMed] 
  47. Cui Q, Wang LT, Liu JZ, Wang HM, Guo N, Gu CB, et al. Rapid extraction of Amomum tsao-ko essential oil and determination of its chemical composition, antioxidant and antimicrobial activities. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1061-1062:364-71. [Crossref]  [PubMed] 
  48. Sabulal N, Baby S. Chemistry of Amomum essential oils. Journal of Essential Oil Research. 2021;33(5):427-41. [Crossref] 
  49. Valiakos E, Marselos M, Sakellaridis N, Constantinidis T, Skaltsa H. Ethnopharmacological approach to the herbal medicines of the "Antidotes" in Nikolaos Myrepsos׳ Dynameron. J Ethnopharmacol. 2015;163:68-82. [Crossref]  [PubMed] 
  50. Sim S, Tan SK, Kohlenberg B, Braun NA. Amomum tsao-ko-Chinese black cardamom: Detailed oil composition and comparison with two other cardamom species. Nat Prod Commun. 2019;14(7):1934578X1985767. [Crossref] 
  51. Dziri S, Casabianca H, Hanchi B, Hosni K. Composition of garlic essential oil (Allium sativum L.) as influenced by drying method. Journal of Essential Oil Research. 2014;26(2):91-6. [Crossref] 
  52. Park HY, Kim ND, Kim GY, Hwang HJ, Kim BW, Kim WJ, et al. Inhibitory effects of diallyl disulfide on the production of inflammatory mediators and cytokines in lipopolysaccharide-activated BV2 microglia. Toxicol Appl Pharmacol. 2012;262(2):177-84. [Crossref]  [PubMed] 
  53. Thuy BTP, My TTA, Hai NTT, Hieu LT, Hoa TT, Thi Phuong Loan H, et al. Investigation into SARS-CoV-2 resistance of compounds in garlic essential oil. ACS Omega. 2020;5(14):8312-20. Erratum in: ACS Omega. 2020;5(26):16315. [Crossref]  [PubMed]  [PMC] 
  54. Islam MN, Hossain KS, Sarker PP, Ferdous J, Hannan MA, Rahman MM, et al. Revisiting pharmacological potentials of Nigella sativa seed: A promising option for COVID-19 prevention and cure. Phytother Res. 2021;35(3):1329-44. [Crossref]  [PubMed]  [PMC] 
  55. Kokoska L, Havlik J, Valterova I, Sovova H, Sajfrtova M, Jankovska I. Comparison of chemical composition and antibacterial activity of Nigella sativa seed essential oils obtained by different extraction methods. J Food Prot. 2008;71(12):2475-80. [Crossref]  [PubMed] 
  56. El Gazzar MA. Thymoquinone suppressses in vitro production of IL-5 and IL-13 by mast cells in response to lipopolysaccharide stimulation. Inflamm Res. 2007;56(8):345-51. [Crossref]  [PubMed] 
  57. Esharkawy ER, Almalki F, Hadda TB. In vitro potential antiviral SARS-CoV-19- activity of natural product thymohydroquinone and dithymoquinone from Nigella sativa. Bioorg Chem. 2022;120:105587. [Crossref]  [PubMed]  [PMC] 
  58. Torres Neto L, Monteiro MLG, Fernández-Romero J, Teleshova N, Sailer J, Conte Junior CA. Essential oils block cellular entry of SARS-CoV-2 delta variant. Sci Rep. 2022;12(1):20639. [Crossref]  [PubMed]  [PMC] 
  59. Senthil Kumar KJ, Gokila Vani M, Wang CS, Chen CC, Chen YC, Lu LP, et al. Geranium and Lemon Essential Oils and Their Active Compounds Downregulate Angiotensin-Converting Enzyme 2 (ACE2), a SARS-CoV-2 Spike Receptor-Binding Domain, in Epithelial Cells. Plants (Basel). 2020;9(6):770. [Crossref]  [PubMed]  [PMC] 
  60. Ali IBE, Tajini F, Boulila A, Jebri MA, Boussaid M, Messaoud C, et al. Bioactive compounds from Tunisian Pelargonium graveolens (L'Hér.) essential oils and extracts: α-amylase and acethylcholinesterase inhibitory and antioxidant, antibacterial and phytotoxic activities. Ind Crops Prod. 2020;158:112951. [Crossref] 
  61. Nabissi M, Marinelli O, Morelli MB, Nicotra G, Iannarelli R, Amantini C, et al. Thyme extract increases mucociliary-beating frequency in primary cell lines from chronic obstructive pulmonary disease patients. Biomed Pharmacother. 2018;105:1248-53. [Crossref]  [PubMed] 
  62. Almaqtari M. Chemical composition and antimicrobial activity of essential oil of Thymus vulgaris from Yemen. Turkish Journal of Biochemistry. 2011;36(4):342-9. [Link] 
  63. Yadav PK, Jaiswal A, Singh RK. In silico study on spice-derived antiviral phytochemicals against SARS-CoV-2 TMPRSS2 target. J Biomol Struct Dyn. 2022;40(22):11874-84. [Crossref]  [PubMed] 
  64. Kumar A, Choudhir G, Shukla SK, Sharma M, Tyagi P, Bhushan A, et al. Identification of phytochemical inhibitors against main protease of COVID-19 using molecular modeling approaches. J Biomol Struct Dyn. 2021;39(10):3760-70. [Crossref]  [PubMed]  [PMC] 
  65. Borugă O, Jianu C, Mişcă C, Goleţ I, Gruia AT, Horhat FG. Thymus vulgaris essential oil: chemical composition and antimicrobial activity. J Med Life. 2014;7 Spec No. 3(Spec Iss 3):56-60. [PubMed]  [PMC] 
  66. Sardari S, Mobaien A, Ghassemifard L, Kamali K, Khavasi N. Therapeutic effect of thyme (Thymus vulgaris) essential oil on patients with Covid19: A randomized clinical trial. Journal of Advances in Medical and Biomedical Research. 2021;29(133):83-91. [Crossref] 
  67. Şakalar Ç, Ertürk M. Inactivation of airborne SARS-CoV-2 by thyme volatile oil vapor phase. J Virol Methods. 2023;312:114660. [Crossref]  [PubMed]  [PMC] 
  68. Sahin Basak S, Candan F. Effect of laurus nobilis L. essential oil and its main components on α-glucosidase and reactive oxygen species scavenging activity. Iran J Pharm Res. 2013;12(2):367-79. [PubMed]  [PMC] 
  69. Sayyah M, Saroukhani G, Peirovi A, Kamalinejad M. Analgesic and anti-inflammatory activity of the leaf essential oil of Laurus nobilis Linn. Phytother Res. 2003;17(7):733-6. [Crossref]  [PubMed] 
  70. Loizzo MR, Saab AM, Tundis R, Statti GA, Menichini F, Lampronti I, et al. Phytochemical analysis and in vitro antiviral activities of the essential oils of seven Lebanon species. Chem Biodivers. 2008;5(3):461-70. [Crossref]  [PubMed]  [PMC] 
  71. Roviello V, Roviello GN. Lower COVID-19 mortality in Italian forested areas suggests immunoprotection by Mediterranean plants. Environ Chem Lett. 2021;19(1):699-710. [Crossref]  [PubMed]  [PMC] 
  72. Le Bon SD, Konopnicki D, Pisarski N, Prunier L, Lechien JR, Horoi M. Efficacy and safety of oral corticosteroids and olfactory training in the management of COVID-19-related loss of smell. Eur Arch Otorhinolaryngol. 2021;278(8):3113-7. [Crossref]  [PubMed]  [PMC] 
  73. Bahl AS, Verma VK, Bhatia J, Arya DS. Integrating in silico and in vivo approach for investigating the role of polyherbal oil in prevention and treatment of COVID-19 infection. Chem Biol Interact. 2022;367:110179. [Crossref]  [PubMed]  [PMC] 
  74. Pelvan E, Serhatlı M, Karaoğlu Ö, Karadeniz B, Pembeci Kodolbaş C, Aslı Öncü N, et al. Development of propolis and essential oils containing oral/throat spray formulation against SARS-CoV-2 infection. J Funct Foods. 2022;97:105225. [Crossref]  [PubMed]  [PMC] 
  75. Lionis C, Karakasiliotis I, Petelos E, Linardakis M, Diamantakis A, Symvoulakis E, et al. A mixture of essential oils from three Cretan aromatic plants (thyme, 2 Greek sage and Cretan dittany, CAPeo) inhibits SASR-CoV- 2 proliferation: in vitro evidence and a proof of concept intervention study in mild ambulatory Covid-19-positive patients. MedRxiv. 2021. [Crossref] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com